

# CD38

## IN BASIC SCIENCE AND CLINICAL PRACTICE

Reflecting on the past to move to the future

13<sup>TH</sup>-14<sup>TH</sup>-15<sup>TH</sup> JULY 2023

CENTRO CONGRESSI GIOVANNI XXIII  
BERGAMO, ITALY

**Organizers:** Claudio Cerchione, Aneel Paulus, Fabio Malavasi  
**Honorary President:** Giovanni Martinelli

**Scientific Board:** K.C. Anderson, M. Boccadoro, S. Bruzzone, P.L. Canonico, C. Cerchione, A. De Flora, A. Gabrielli, A.L. Horenstein, F. Malavasi, G. Martinelli, P. Moreau, A. Paulus, P.G. Richardson, J. San Miguel, C. Terhorst, A. Sikander, A. Chanan-Khan

**Scientific Secretariat:** C. Cerchione, A. C. Faini, F. Malavasi, A. Paulus, M. Rocca

WITH THE PATRONAGE OF



info@proeventi.it  
www.proeventi.it

**Organizers:**Claudio **Cerchione****IRST, Meldola (FC)**Aneel **Paulus****Mayo Clinic, Jacksonville**Fabio **Malavasi****Università di Torino  
Fondazione Ricerca Molinette, Turin****Honorary President:**Giovanni **Martinelli****IRST, Meldola (FC)****The Conference has been accredited to the Italian Ministry of Health:**

Event n. 362745

Provider n. 2773


**17 ECM credits** for Physicians, Nurses, Biologists, TSLBs, Pharmacists

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

# WITH PATRONAGE



 **SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA**  
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUT  
ROMAGN  
PER LO  
DEI TUM  
DINO  
AMADORI


# ORGANIZING INSTITUTIONS





# SUMMARY

- 6 **SCIENTIFIC RATIONALE**
- 8 **SCIENTIFIC BOARD**
- 9 **SCIENTIFIC SECRETARIAT**
- 10 **THURSDAY, JULY 13<sup>TH</sup>**
- 12 **FRIDAY, JULY 14<sup>TH</sup>**
- 15 **SATURDAY, JULY 15<sup>TH</sup>**
- 17 **SUPPORTED BY**



## SCIENTIFIC RATIONALE

Over 3 decades of research on CD38 and their role in human diseases has recently culminated in the development of agents that target CD38 for therapeutic exploit. The formal approval and expanding use of anti-CD38 therapeutic antibodies has emerged as an important treatment modality for the clinical management of patients with multiple myeloma. On the heels of this success, the efficacy of CD38-targeting agents is being actively investigated for patients with other hematologic malignancies, solid tumour cancers, autoimmune disorders as well as pathologies related to ageing, neurodegenerative disorders, neuropsychology, and cardiovascular disease. With an abundance of scientific data being released on CD38 biology and development of novel anti-CD38 therapies, our meeting, entitled, “CD38 in Basic Science and Clinical Practice: Reflecting on the past to move to the Future” is timely and will bring together experts investigating the role of CD38 in cancer, ageing, autoimmunity and neurology and psychology. This important conference will foster much needed engagement between clinicians, basic-science researchers and pharmaceutical companies working on CD38. As anti-CD38 therapies are currently approved for use in patients with multiple myeloma, a major theme of the meeting will be on the optimal use of these agents and novel therapeutic strategies once patients stop responding to targeted interference of CD38. The meeting is being organized by experts in the field (Drs. Cerchione, Paulus and Malavasi) with the support of their respective academic institutes and patronage from various pharmaceutical partners, professional societies, and philanthropists.

# SCIENTIFIC BOARD

Kenneth C. **Anderson**

Mario **Boccardo**

Santina **Bruzzo**

Pier Luigi **Canonico**

Claudio **Cerchione**

Antonio **De Flora**

Armando **Gabrielli**

Alberto L. **Horenstein**

Fabio **Malavasi**

Giovanni **Martinelli**

Philippe **Moreau**

Aneel **Paulus**

**Boston**

**Turin**

**Genova**

**Vercelli**

**Meldola (FC)**

**Genova**

**Ancona**

**Turin**

**Turin**

**Meldola (FC)**

**Nantes**

**Jacksonville**



Paul G. **Richardson**

**Boston**

Jesus **San Miguel**

**Navarra**

Cornelis **Terhorst**

**Boston**

Ailawadhi **Sikander**

**Jacksonville**

Asher **Chanan-Khan**

**Jacksonville**

# SCIENTIFIC SECRETARIAT

Claudio **Cerchione**

**Meldola (FC)**

Angelo Corso **Faini**

**Turin**

Fabio **Malavasi**

**Turin**

Aneel **Paulus**

**Jacksonville**

Marzia **Roccia**

**Turin**

**Thursday, July 13<sup>th</sup>**



**13:00 INTRODUCTION AND PRESENTATION OF THE EVENT**

Claudio Cerchione, Fabio Malavasi, Giovanni Martinelli, Aneel Paulus

**1<sup>st</sup> SESSION - FROM BIOLOGY TO POTENTIAL CLINICAL APPLICATIONS**

Chairs: Asher Chanan-Khan, Claudio Cerchione, Aneel Paulus, Paola Storti

**13:15-13:45 Magistral Lecture:**

**The new treatment landscape of hematologic diseases**

**Alessandro Rambaldi**

**13:45-14:05** CD38 in CLL

**Aneel Paulus**

**14:05-14:25** CD38 and COVID-19

**Alberto L. Horenstein**

**14:25-14:45** Role of CD38 in the myeloma bone microenvironment

**Nicola Giuliani**

**14:45-15:05** Targeting CD38-expressing cells with nanobody-based Abs, BiKEs, CARs and AAV

**Julia Hambach**

**15:05-15:25** Role of CD38 in adipocytes and muscle tissues

**Santina Bruzzone**

**15:25-15:50 Discussion**

**15:50-16:15 Coffee Break**

**2<sup>nd</sup> SESSION - CD38 IN BASIC SCIENCE**

Chairs: Santina Bruzzone, Fabio Malavasi, Michele Cea

**16:15-16:35** Localized prostate cancer treated with daratumumab and CSF-1R inhibitor

**Bilal A. Siddiqui**

**16:35-16:55** Tunnelling nanotubules in MM metabolism

**Stuart Rushworth**

**16:55-17:15** Immunotherapy in Multiple Myeloma: rationale of anti-CD38/immunomodulators combination

**Roberto Ria**

**17:15-17:35** Key steps in the therapeutic application of anti-CD38 in Multiple Myeloma

**Mohamad Mohty**

**17:35-18:00 Discussion**

**JUNIOR SESSION**

Chairs: Ruxandra-Maria Irimia, Angelo Corso Faini

**18:00-18:20** Expression of CD38 in Mast Cells: Cytological and Histotopographic Features

**Dmitri Atiakshin**

**18:20-18:40** Use of daratumumab in refractory red cell aplasia and refractory hemolytic anemia after allogeneic hematopoietic stem cell transplantation

**Maria Assunta Limongiello**

**Friday, July 14<sup>th</sup>**

**3<sup>rd</sup> SESSION – HOW ANTI-CD38 ANTIBODIES CHANGED THE OUTCOME OF MULTIPLE MYELOMA**

Chairs: Kenneth C. Anderson, Claudio Cerchione, Claudia Chini, Paul G. Richardson

**09:00-09:30** Special Lecture 1: Novel therapies and future directions in the new complex, and crowded therapeutic scenario of Multiple Myeloma  
**Kenneth C. Anderson**

**09:30-10:00** From an ugly duckling to a beautiful swan: The fairy tale of daratumumab  
**Torben Plesner**

**10:00-10:30** Unlock the potential of anti-CD38 in multiple myeloma: differential mechanisms of action and clinical data  
**Xavier Leleu**

**10:30-11:00** The evolving therapeutic landscape for the upfront treatment of Multiple Myeloma: doublet to triplet, quadruplet and beyond. A clinical and strategic perspective  
**Paul G. Richardson**

**11:00-11:20** Correct sequencing of ultranovel agents in relapsed refractory Myeloma  
**Jesus San Miguel**

**11:20-11:35** **Discussion**

**11:35-11:50** **Coffee Break**

**4<sup>th</sup> SESSION – CD38 AND CLINICAL APPLICATIONS**

Chairs: Michele Cavo, Claudio Cerchione, Maria Victoria Mateos

**11:50-12:10** How I treat frontline Multiple Myeloma and Smoldering Myeloma in Europe – Focus on anti-CD38 antibodies  
**Maria Victoria Mateos**

**12:10-12:30** How I treat relapsed/refractory Multiple Myeloma in Europe – Focus on anti-CD38 antibodies  
**Meletios Athanasios Dimopoulos**

**12:30-12:50** How to integrate monoclonal antibodies in Multiple Myeloma in Italy

**Claudio Cerchione**

**12:50-13:10** Retargeting CD38 in anti-CD38 exposed and/or refractory Myeloma

**Hans C. Lee**

**13:10-13:40 Lunch Time**

### **5<sup>th</sup> SESSION – CD38 DEBATES**

Chairs: Torben Plesner, Paul G. Richardson, Jesus San Miguel

**13:40-14:00 Debate:**

How long to treat: until progressive disease versus fixed duration

**Michele Cavo vs Philippe Moreau**

**14:00-14:20 Debate:**

Upfront anti-CD38 drugs for everyone or for selected patients: YES versus NO

**Claudio Cerchione vs Roberto Mina**

**14:20-14:40** EMN clinical trials anti-CD38-based

**Mario Boccadoro**

### **6<sup>th</sup> SESSION – BEYOND MONOCLONAL ANTIBODIES**

Chairs: Fabio Malavasi, Aneel Paulus

**14:40-15:00** Targeting CD38 in mature T-cell neoplasms

**Anjali Mishra**

**15:00-15:20** Myeloma therapy and microvesicles

**Fabio Morandi**

**15:20-15:40** Multiple Myeloma Plasma Extracellular Vesicles from patients treated with Daratumumab show elevated levels of complement inhibitory proteins CD55 and CD59

**Kieran Brennan**

## Friday, July 14<sup>th</sup>



**15:40-16:00** CD38 targeting in the treatment of AL Amyloidosis  
**Giovanni Palladini**

**16:00-16:20** CD38-directed Therapy for Acute Myeloid Leukemia  
**Talha Badar**

**16:20-16:30 Discussion**

**Open Coffee Break**

### **7<sup>th</sup> SESSION – BEYOND MULTIPLE MYELOMA**

Chairs: Claudio Cerchione, Ailawadhi Sikander, Evangelos Terpos

**16:30-16:50** Bispecific monoclonal antibodies and CAR-T anti-myeloma cells  
**Ailawadhi Sikander**

**16:50-17:10** A phase 2 trial (ALLG MM21) of an immunotherapeutic salvage approach (daratumumab-revlimid-dexamethasone) for patients failing front-line bortezomib-based induction  
**Andrew Spencer**

**17:10-17:30** Management of myeloma-related bone disease  
**Evangelos Terpos**

**17:30-17:50 Discussion**

**Conclusion: Claudio Cerchione, Fabio Malavasi, Aneel Paulus**

**8<sup>th</sup> SESSION – AGING**

Chairs: Eduardo Nunes Chini, Armando Gabrielli

**09:00-09:20** Evolving concepts in NAD metabolism

**Eduardo Nunes Chini**

**09:20-09:40** CD38 and fibrosis

**John Varga**

**09:40-10:00** Mitochondrial metabolic checkpoint, stem cell aging and rejuvenation

**Danica Chen**

**10:00-10:20** CD38 as a new therapeutic target for Duchenne Muscular Dystrophy

**Jose Manuel Cancela**

**10:20-10:40** Cell-specific roles of CD38 in NAD metabolism

**Claudia Chini**

**10:40-11:00** Development of CD38-binding radiotheranostics

**Jo Caers**

**11:00-11:20 Discussion**

**9<sup>th</sup> SESSION – PSYCHOLOGY/PSYCOPATHOLOGY**

Chairs: Richard Ebstein, Alla B. Salmina

**11:20-11:40** Blending oxytocin, dopamine and CD38 with everyday creativity

**Richard Ebstein**

**11:40-12:00** CD38 and learning

**Bong-Kiun Kaang**

**12:00-12:20** CD38-controlled mitochondrial dynamics and metabolism in neurodegeneration

**Alla B. Salmina**

## Saturday, July 15<sup>th</sup>



**12:20-12:40** CD38-dependent social behavior

**Olga L. Lopatina**

**12:40-13:00** CD38 and oxytocin

**Daniel S. Quintana**

**13:00-13:20** CD38, CD157, and nicotinamide riboside, a precursor of NAD, play important roles in social behavior

**Haruhiro Higashida**

**13:20-13:40 Discussion**

**13:40 CONCLUSIONS AND SEE YOU NEXT YEAR**

Claudio Cerchione, Fabio Malavasi, Aneel Paulus



**SUPPORTED**

BY





Graphic Designer: **Mario Titone**  
[www.mariotitone.com](http://www.mariotitone.com)